在糖尿病并发症中PACAP的保护作用:视网膜病变,病变和神经病变
Dora Reglodi1, Andrea Tamas1, Inez Bosnyak1
1HUN REN-PTE PACAP Research Group, Department of Anatomy, University of Pecs Medical School, 7624 Pecs, Hungary.
International journal of molecular sciences
|October 16, 2025
概括
下垂体腺酸环酶激活聚 (PACAP) 提供了预防糖尿病并发症的保护作用. PACAP的使用改善了视网膜病变,病变和神经病变模型的结果,突出了其治疗潜力.
科学领域:
- 内分泌学 在内分泌学.
- 神经科学是一个神经科学.
- 眼科医生 眼科 眼科
- 腎臟病學 (nephrology) 是一種醫學專業.
- 糖尿病学 糖尿病学
背景情况:
- pituitary adenylate cyclase-activating polypeptide (PACAP) 是一种具有重要的营养和保护功能的神经.
- PACAP 影响葡萄糖平衡,并通过其PAC1受体发挥保护作用,激活抗炎,抗丧和抗氧化途径.
研究的目的:
- 审查PACAP在主要糖尿病相关并发症中的保护作用:视网膜病变,病变和神经病变.
- 总结PACAP在糖尿病引起的疾病中的其他有益作用.
主要方法:
- 在1型和2型糖尿病视网膜病变模型中审查涉及PACAP的研究.
- 对神经病和糖尿病神经病模型中PACAP的研究分析.
- 检查PACAP对暴露于葡萄糖的细胞和其他糖尿病并发症的影响.
主要成果:
- 在糖尿病视网膜病变模型中,PACAP抵消了视网膜退化,抑制了细胞亡,并减少了异常血管生长.
- 在病模型中,PACAP保留了形态,减少了亡和纤维化.
- 在糖尿病神经病变和减少疼痛中心激活时,PACAP 保护了对轴突-髓病变的保护.
结论:
- PACAP显示出针对主要糖尿病并发症的显著保护作用,包括视网膜病变,病变和神经病变.
- 神经也显示在其他糖尿病相关问题,如血管功能障碍,认知缺陷和动脉样硬化的好处.
- 开发基于PACAP的治疗方法是解决目前糖尿病治疗的局限性的有希望的途径.
更多相关视频
相关概念视频
01:20Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
01:26Peripheral Artery Disease IV: Nursing Management
347
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
347
01:27Peripheral Artery Disease III: Interprofessional Care
237
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
237
01:23Dipeptidyl Peptidase 4 Inhibitors
581
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
581
01:15Diabetes: Management and Pharmacotherapy
861
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
861